Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PYPD vs ABOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Captures Overall Composite Edge (31.1 SELL vs 49.5 HOLD), While ABOS Leads 2–1 on Growth & Valuation Pillars

PYPD Overall Winner 6-Pillar Tally: PYPD 1 – 2 ABOS (3 Tie) Matrix Metrics: PYPD 3 – 2 ABOS

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.1/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 3–2 (led by Options & Positioning), while ABOS wins 2–1 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus ABOS at $0.22 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PYPD vs ABOS
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.50
+5.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.88β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.22
+2.08% 1D
Market Cap $15.5M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.61β · 327% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.8%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $0.91 · SMA50: $1.73

6-Pillar Scorecard Institutional Category Breakdown (PYPD 1 – 2 ABOS)

Columns: Metric · PYPD · ABOS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $329,000
Market Cap $132.2M $15.5M
3. Profitability & Quality ABOS
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -243.6% -162.7%
4. Balance Sheet & Cash Flow ABOS
Cash Generation (TTM) N/A -$105M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.0M Net Cash $27M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 106.3% (12th %ile) 232.4% (41st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PYPD (3) vs ABOS (2)
Institutional Metric PYPD ABOS Criterion Row Edge
Market Capitalization
Scale
$132.2M $15.5M Larger Scale PYPD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-243.6% -162.7% Higher ROE ABOS
52-Week Range Position
Momentum
82% ($4–$7) 1% ($0–$4) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.88β · 59% Vol 2.61β · 327% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 49.5 / 100 (HOLD) Higher Composite ABOS
Trailing 12M Revenue (USD)
Operating Scale
N/A $329,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash) -$105M EBITDA ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +120.66 pp
PYPD: +33.12% · ABOS: -87.54%
3M Horizon PYPD +122.66 pp
PYPD: +29.66% · ABOS: -93.0%
6M Horizon PYPD +126.31 pp
PYPD: +36.47% · ABOS: -89.84%
1Y Horizon PYPD +168.2 pp
PYPD: +80.95% · ABOS: -87.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs ABOS. Trailing 12-month operating profitability (PYPD 0.0% vs ABOS 0.0%) and valuation multiples (PYPD N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M
ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PYPD vs ABOS Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) captures the overall head-to-head institutional edge over Acumen Pharmaceuticals, Inc. (ABOS) on higher Unified Composite conviction (31.1/100 SELL vs. 49.5/100 HOLD) after splitting the core matrix 3–2 (led by Options & Positioning), while ABOS wins 2–1 across the 6-pillar growth and valuation breakdown. PYPD trades at $6.50 (N/M Forward P/E, 0.0% operating margin) versus ABOS at $0.22 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABOS currently prints a higher short-term Unified Composite Score (49.5/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PYPD and ABOS split Growth & Scale metrics: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.

PYPD and ABOS trade at balanced relative valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus ABOS (-162.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.88β · 59% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 327% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.